AMAG PHARMACEUTICALS INC.

Form 4

August 28, 2013

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

Expires:

3235-0287 January 31,

0.5

Check this box if no longer

subject to Section 16. STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Estimated average burden hours per

OMB APPROVAL

response...

Form 4 or Form 5 obligations may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

See Instruction

1(b).

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * ADAGE CAPITAL PARTNERS GP LLC

2. Issuer Name **and** Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

Symbol

AMAG PHARMACEUTICALS

(Check all applicable)

INC. [AMAG]

(Middle)

3. Date of Earliest Transaction

___ Director ___X__ 10% Owner Officer (give title _____ Other (specify

(Month/Day/Year)

08/26/2013

Officer (give title Ofbelow)

200 CLARENDON STREET, 52ND

(Street)

(First)

FLOOR,

(Last)

4. If Amendment, Date Original

Applicable Line)

Filed(Month/Day/Year)

___ Form filed by One Reporting Person
X Form filed by More than One Reporting

6. Individual or Joint/Group Filing(Check

Person

BOSTON, MA 02116

| (City) | (State) (Z | ^{Zip)} Table | I - Non-De | erivative S | ecurit | ies Acqui | red, Disposed of | or Beneficial | ly Owned |
|---|---|---|--|-----------------------------------|--------------------------------|-------------|--|--|---|
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transactic Code (Instr. 8) | 4. Securit on(A) or Di (Instr. 3, | sposed 4 and : (A) or | d of (D) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Common Stock, par value \$.01 per share ("Common Stock") (1) | 08/26/2013 | | D | 3,100 | D | \$ 25 | 3,875,692 | I | See Footnote (1) |
| Common Stock | 08/27/2013 | | D | 12,000 | D | \$ 25.02 | \$ 3,863,692 | I | See Footnote (1) |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: AMAG PHARMACEUTICALS INC. - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of | 2. | 3. Transaction Date | 3A. Deemed | 4. | 5. | 6. Date Exerc | | 7. Titl | e and | 8. Price of | 9. Nu |
|-------------|-------------|---------------------|--------------------|------------|------------|---------------|------------|---------|----------|-------------|--------|
| Derivative | Conversion | (Month/Day/Year) | Execution Date, if | Transacti | orNumber | Expiration D | ate | Amou | nt of | Derivative | Deriv |
| Security | or Exercise | | any | Code | of | (Month/Day/ | Year) | Under | lying | Security | Secu |
| (Instr. 3) | Price of | | (Month/Day/Year) | (Instr. 8) | Derivative | e | | Securi | ities | (Instr. 5) | Bene |
| | Derivative | | | | Securities | | | (Instr. | 3 and 4) | | Owne |
| | Security | | | | Acquired | | | | | | Follo |
| | | | | | (A) or | | | | | | Repo |
| | | | | | Disposed | | | | | | Trans |
| | | | | | of (D) | | | | | | (Instr |
| | | | | | (Instr. 3, | | | | | | |
| | | | | | 4, and 5) | | | | | | |
| | | | | | | | | | Amount | | |
| | | | | | | | | | or | | |
| | | | | | | Date | Expiration | Title | Number | | |
| | | | | | | Exercisable | Date | | of | | |
| | | | | Code V | (A) (D) | | | | Shares | | |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | | | |
|--|---------------|-----------|---------|-------|--|--|--|
| | Director | 10% Owner | Officer | Other | | | |
| ADAGE CAPITAL PARTNERS GP LLC 200 CLARENDON STREET, 52ND FLOOR BOSTON, MA 02116 | | X | | | | | |
| Adage Capital Partners, L.P. 200 CLARENDON STREET, 52ND FLOOR BOSTON, MA 02116 | | X | | | | | |
| Adage Capital Advisors, L.L.C. 200 CLARENDON STREET 52ND FLOOR BOSTON, MA 02116 | | X | | | | | |
| Atchinson Robert 200 CLARENDON STREET 52ND FLOOR BOSTON, MA 02116 | | X | | | | | |
| Gross Phillip 200 CLARENDON STREET 52ND FLOOR BOSTON, MA 02116 | | X | | | | | |

Reporting Owners 2

Signatures

| /s/ Adage Capital Partners GP, L.L.C.; By its managing member Adage Capital Advisors, | | | | | |
|--|--------------------|--|--|--|--|
| L.L.C.; By its managing member Robert Atchinson | | | | | |
| **Signature of Reporting Person | Date | | | | |
| /s/ Adage Capital Partners, L.P.; By its general partner Adage Capital Partners GP, L.L.C.; By its managing member Adage Capital Advisors, L.L.C.; By its managing member Robert Atchinson | | | | | |
| **Signature of Reporting Person | Date | | | | |
| /s/ Adage Capital Advisors, L.L.C.; By its managing member Robert Atchinson **Signature of Reporting Person | 08/28/2013 Date | | | | |
| /s/ Robert Atchinson | 08/28/2013 | | | | |
| **Signature of Reporting Person | Date | | | | |
| /s/ Phillip Gross | 08/28/2013 | | | | |
| **Signature of Reporting Person | Date | | | | |

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - Adage Capital Partners GP, L.L.C., a Delaware limited liability company ("ACPGP"), serves as the general partner of Adage Capital Partners, L.P., a Delaware limited partnership (the "Fund"), and as such has discretion over the portfolio securities beneficially owned by
- the Fund. Adage Capital Advisors, L.L.C., a Delaware limited liability company ("ACA"), is the managing member of ACPGP and directs ACPGP's operations. Robert Atchinson and Phillip Gross are the managing members of ACPGP and ACA and general partners of the Fund. ACPGP, ACA, Robert Atchinson and Phillip Gross disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3